"Anti-Asthmatic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that are used to treat asthma.
| Descriptor ID |
D018927
|
| MeSH Number(s) |
D27.505.954.796.050
|
| Concept/Terms |
Anti-Asthmatic Agents- Anti-Asthmatic Agents
- Agents, Anti-Asthmatic
- Anti Asthmatic Agents
- Anti-Asthmatics
- Anti Asthmatics
- Antiasthmatic Drugs
- Drugs, Antiasthmatic
- Antiasthmatics
- Anti-Asthmatic Drugs
- Anti Asthmatic Drugs
- Drugs, Anti-Asthmatic
- Antiasthmatic Agents
- Agents, Antiasthmatic
|
Below are MeSH descriptors whose meaning is more general than "Anti-Asthmatic Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-Asthmatic Agents".
This graph shows the total number of publications written about "Anti-Asthmatic Agents" by people in this website by year, and whether "Anti-Asthmatic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 2 | 1 | 3 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 2 | 1 | 3 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 2 | 4 |
| 2008 | 1 | 0 | 1 |
| 2009 | 3 | 1 | 4 |
| 2010 | 2 | 3 | 5 |
| 2011 | 1 | 1 | 2 |
| 2012 | 2 | 1 | 3 |
| 2013 | 0 | 2 | 2 |
| 2014 | 2 | 2 | 4 |
| 2015 | 6 | 0 | 6 |
| 2016 | 2 | 2 | 4 |
| 2017 | 4 | 0 | 4 |
| 2018 | 7 | 1 | 8 |
| 2019 | 5 | 1 | 6 |
| 2020 | 7 | 1 | 8 |
| 2021 | 4 | 1 | 5 |
| 2022 | 6 | 0 | 6 |
| 2023 | 6 | 1 | 7 |
| 2024 | 4 | 1 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-Asthmatic Agents" by people in Profiles.
-
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences. Drugs. 2024 Oct; 84(10):1251-1273.
-
Biologics in Asthma: Emerging Biologics. Immunol Allergy Clin North Am. 2024 Nov; 44(4):751-763.
-
Characterization of Moderate and Severe Asthma Exacerbations in the CAPTAIN Study. J Allergy Clin Immunol Pract. 2024 Sep; 12(9):2372-2380.e5.
-
Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population. J Allergy Clin Immunol Pract. 2024 May; 12(5):1215-1224.e3.
-
Effectiveness of omalizumab across different dosing regimens in patients with moderate-to-severe allergic asthma. Respir Med. 2024 03; 223:107537.
-
Tezepelumab in patients with allergic and eosinophilic asthma. Allergy. 2024 05; 79(5):1134-1145.
-
Influence of baseline bronchodilator reversibility and blood eosinophils on lung function in patients with asthma following omalizumab. J Allergy Clin Immunol Pract. 2024 02; 12(2):512-514.e2.
-
Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient. Respir Med. 2023 11; 218:107414.
-
Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitization. Clin Exp Allergy. 2023 10; 53(10):1020-1030.
-
Revisiting asthma pharmacotherapy: where do we stand and where do we want to go? Eur Respir J. 2023 08; 62(2).